히드록시프로필메칠셀룰로오스 프탈레이트 및 에칠셀룰로오스를 이용한 이부딜라스트 함유서방성 매트릭스 정제의 개발
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 오동훈 | - |
dc.contributor.author | 이종달 | - |
dc.contributor.author | 유동성 | - |
dc.contributor.author | 장기영 | - |
dc.contributor.author | 임종섭 | - |
dc.contributor.author | 성정훈 | - |
dc.contributor.author | 한묘정 | - |
dc.contributor.author | 권태협 | - |
dc.contributor.author | 양호준 | - |
dc.contributor.author | 박병철 | - |
dc.contributor.author | 이종숙 | - |
dc.contributor.author | 용철순 | - |
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2021-06-23T20:05:19Z | - |
dc.date.available | 2021-06-23T20:05:19Z | - |
dc.date.created | 2021-02-01 | - |
dc.date.issued | 2007-12 | - |
dc.identifier.issn | 2093-5552 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/43932 | - |
dc.description.abstract | To develop a sustained-release tablet which had the similar dissolution to commercial ibudilast-loaded sustained-release capsule, the tablets were prepared using hydroxypropylmethylcellulose phthalate (HPMCP), ethylcellulose (EC) and hydroxypropylcellulose (HPC), and dissolution test were carried out with paddle method in KP. The tablet prepared only with HPMCP and EC showed sno similar dissolution pattern to the commercial product. As the ratio of HPMCP/HPC in tablet decreased, the dissolution rate of drug decreased in pH 1.2 but increased in pH 6.8. Furthermore, an ibudilast-loaded sustained-release tablet composed of [ibudilast/EC/HPMCP/HPC (10/10/170/10 mg/tab)] gave similar dissolution to commercial product in pH 1.2 for 3 h and in pH 6.8 for 10 h. Thus, it could be a potential candidate for the substitute of commercial capsule. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 한국약제학회 | - |
dc.title | 히드록시프로필메칠셀룰로오스 프탈레이트 및 에칠셀룰로오스를 이용한 이부딜라스트 함유서방성 매트릭스 정제의 개발 | - |
dc.title.alternative | Formulation of Sustained Release Matrix Tablets Containing Ibudilastwith Hydroxypropylmethylcellulose Phthalate and Ethylcellulose | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 최한곤 | - |
dc.identifier.doi | 10.4333/KPS.2007.37.6.355 | - |
dc.identifier.bibliographicCitation | Journal of Pharmaceutical Investigation, v.37, no.6, pp.355 - 358 | - |
dc.relation.isPartOf | Journal of Pharmaceutical Investigation | - |
dc.citation.title | Journal of Pharmaceutical Investigation | - |
dc.citation.volume | 37 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 355 | - |
dc.citation.endPage | 358 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001208827 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Ibudilast | - |
dc.subject.keywordAuthor | Sustained release tablet | - |
dc.subject.keywordAuthor | Dissolution | - |
dc.subject.keywordAuthor | HPMCP | - |
dc.subject.keywordAuthor | EC | - |
dc.subject.keywordAuthor | HPC | - |
dc.identifier.url | https://www.koreascience.or.kr/article/JAKO200706414521080.page | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.